Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s research stage gene therapy discovery programs. Financial terms were not disclosed.



Evotec GT is part of Evotec’s modality-agnostic drug discovery platform that combines all activities involved with the discovery, development, and manufacturing of therapeutics along the value chain.



Under the alliance, Evotec will support multiple Takeda programs targeting conditions aligned with Takeda’s four core therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology. The alliance leverages Evotec’s gene therapy capabilities as well as its broader drug discovery platform.



Dr. Steven Hitchcock, Global Head of Research for Takeda, said: “We are excited to be broadening and expanding our discovery efforts with the Evotec team. Gene therapy is a growing therapeutic approach in our portfolio and this alliance with Evotec will help us further accelerate our delivery of transformative therapies for patients, particularly those with rare diseases.”



Dr. Craig Johnstone, Chief Operating Officer of Evotec, said, “We’re pleased to expand the scope of our collaboration with Takeda into gene therapy by establishing an alliance with Takeda. This new alliance demonstrates the value of our multimodality platform with innovative technologies and best-in-class execution for addressing the most urgent requirements of our partners. Relationships like this will transform industry’s approach to drug discovery and development to ultimately find new therapies.”